Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Krystal Biotech, Inc.
KRYS
NASDAQ·Healthcare·Biotechnology·Mkt cap $11.0B
$375.07
▲ +0.94%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$130.50 - $382.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 162.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary redosable gene therapy platform enabling repeat dosing
- First-mover advantage in DEB gene therapy with Phase III clinical data
- Diversified pipeline addressing multiple rare disease indications
- Focused expertise in cutaneous and genetic disorder applications
Bear Case
2 risks
- Low volatility (beta 0.5).
- High premium - requires strong execution
Growth
Strong growth ahead
Phase III clinical trial progression and potential FDA approval of B-VEC
Value
High premium - requires strong execution
Momentum
Hot
+42.4% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KRYS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 4, 2026
Reported EPS of $1.83 vs $1.45 consensus (+26.2% surprise). Revenue of $116.4M vs $112.1M expected (+3.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+26.2%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
+116%
+95%
+37%
+17%
+18%
+32%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$70.3M
$83.8M
$91.1M
$88.2M
$96.0M
$97.8M
$107.1M
$116.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
48.1%
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$300.00
▼ -20.0% vs $375.07
Latest: HC Wainwright · Jun 16, 2026
1 analyst covering